Cardiff University researchers shed light on development of gastric cancer

January 29, 2019

Cardiff University researchers have uncovered new information about the underlying mechanisms for gastric cancer, providing hope of potential new therapies in the future.

The team, at the University's European Cancer Stem Cell Research Institute, found they could stop gastric cells dividing and growing by deleting a particular cell-surface receptor implicated in the function of stem cells.

Dr Toby Phesse, Cardiff University, said: "The prognosis of gastric cancer is very poor, with very few treatment options available to patients, and thus we desperately need new clinical treatments for this disease.

"Some patients with gastric cancer have mutations in genes that are involved in the regulation of Wnt - a cell signalling pathway involved in cell division. It drives the development of cancer and the spread of cancers throughout the body.

"We also see an increase in some of the Fzd receptors, which transmit Wnt signalling, and this is linked to poor prognosis in gastric cancer.

"Despite this evidence, there is limited research investigating the potential of targeting Wnt receptors as a treatment for gastric cancers. We aimed to understand the implications of inhibiting Wnt by targeting Fzd receptors and whether this could be used as an effective treatment."

The scientists targeted a specific Fzd receptor called Fzd7, as this was identified the predominant Wnt receptor responsible for the function of stem cells in the stomach and intestine. They found that deletion of Fzd7 in gastric cells made these cells unable to respond to Wnt signals and they failed to divide and grow.

Dr Phesse added: "This information gives us a potential new therapeutic route for gastric cancers, as we could target Fzd7 and consequently inhibit Wnt signalling and tumour growth. In fact, Vantictumab is a drug known to inhibit several Fzd receptors, including Fzd7, and is currently in clinical trials for the treatment of other cancers - like pancreatic, lung and breast.

"We have now shown in this work that Vantictumab has potent anti-tumour effects in gastric tumours with and without mutations to the Wnt pathway.

"This research extends the scope of patients that may benefit from this therapy, to now include gastric cancer patients, and future work will establish if we can proceed with clinical trials targeting Wnt receptors for this devastating disease."
-end-
This research, in collaboration with the University of Melbourne, University Medical Center Utrecht, the Institute of Medical Biology Singapore, and Oncomed Pharmaceuticals, is published online in Cancer Research, a journal of the American Association for Cancer Research.

Cardiff University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.